Novo Nordisk, Eli Lilly fall after Trump comments on weight loss drug pricing
Halozyme Therapeutics Inc stock has reached an all-time high, touching 74.79 USD. According to InvestingPro data, the company boasts a perfect Piotroski Score of 9, indicating exceptional financial strength. With a market capitalization of $8.7 billion and an impressive 35% revenue growth in the last twelve months, the company’s fundamentals support this milestone. This milestone reflects a significant upward trajectory for the company’s shares, marking a notable increase in investor confidence and market performance. Over the past year, Halozyme Therapeutics has experienced a robust 20.04% increase in its stock value, while delivering a remarkable 77.5% gross profit margin. The company’s strong market momentum is further validated by seven analysts revising their earnings estimates upward. This achievement highlights the company’s growth potential and positions it favorably within the biotechnology sector. For deeper insights into Halozyme’s valuation and 19 additional ProTips, explore the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Halozyme Therapeutics reported its second-quarter 2025 earnings, which showed a significant earnings per share (EPS) beat but fell short of revenue expectations. The company achieved an EPS of $1.54, exceeding the forecasted $1.24 by 24.19%, while revenue reached $206 million, which was considerably below the anticipated $286.01 million. Following this, Citizens JMP raised its price target for Halozyme to $91, citing the company’s financial performance and increased guidance for 2025. Additionally, Morgan Stanley upgraded Halozyme to Overweight and increased its price target to $75, attributing the positive outlook to the ORPHAN Cures Act included in recent legislation. Meanwhile, Goldman Sachs raised its price target slightly to $56, maintaining a Neutral rating, based on the analysis of the Inflation Reduction Act’s potential impact. These developments reflect the varied perspectives of analysts on Halozyme’s future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.